Study was funded by Sobi and Sanofi.

Publication

ISTH •
25 June, 2024 •
•

Long-term Outcomes With Efanesoctocog Alfa Prophylaxis for Previously Treated Children With Severe Hemophilia A, an Interim Analysis of the Phase 3 XTEND-ed Study

Lynn Malec, Beatrice Nolan, Anthony KC Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Oral Presentation

Publication

ISTH •
23 June, 2024 •
•

Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program

Anthony KC Chan, Sophie Susen, Liane Khoo, Annette von Drygalski, Johannes Oldenburg, Ming-Ching Shen, Flora Peyvandi, Cristina Tarango, Pratima Chowdary, Lara Mamikonian, Helena Palmborg, Jennifer Dumont , Elena Santagostino, Cedric Hermans

Available materials

Oral Presentation

Publication

ISTH •
22 June, 2024 •
•

Long-Term Joint Health Outcomes With a Recombinant Factor VIII Fc From the 48-Month Prospective, Observational A-MORE Study: Third Interim Analysis of Up to 24 Months

Jan Astermark, Johannes Oldenburg, Ruben Berrueco, Annarita Tagliaferri, Mikaela Alenäs, Markus Fusser, Stefan Lethagen

Available materials

Poster

First Interim Analysis of Clinical Outcomes in Adults and Adolescents With Severe Hemophilia A Receiving Efanesoctocog Alfa Prophylaxis in XTEND-ed, a Phase 3 Long-term Extension Study

Long-term Outcomes With Efanesoctocog Alfa Prophylaxis for Previously Treated Children With Severe Hemophilia A, an Interim Analysis of the Phase 3 XTEND-ed Study

Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program

Long-Term Joint Health Outcomes With a Recombinant Factor VIII Fc From the 48-Month Prospective, Observational A-MORE Study: Third Interim Analysis of Up to 24 Months

Joint health outcomes with efanesoctocog alfa in adults/adolescents from XTEND-1 continuing XTEND-ed

Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Observational Study of Prophylactic Efanesoctocog Alfa for Joint Health in Hemophilia A: PROTECT-ALT

Long-term observational joint health study in patients initiating efanesoctocog alfa: baseline data